Research Article
Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
Figure 3
Differential effects of ribociclib on the CDK4/6-cyclin D-pRb signaling in RCC. (a) The representative western blot photo shows decreased and unchanged level of p-Rb at two phosphorylation sites in sensitive () and resistant () RCC cell lines, respectively. (b) The decreased and unchanged transcriptional level of E2F target genes: FOXM1, CCNE1, and MSH6 in RCC cell lines. Cells were treated with ribociclib for 24 hours prior to western blot and mRNA level analysis. , compared to control.
(a) |
(b) |
(c) |
(d) |